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Abstract
Background: Exome and genome sequencing are routinely used in clinical care and research. These technologies
allow for the detection of pathogenic/likely pathogenic variants in clinically actionable genes. However, fueled in
part by a lack of empirical evidence, controversy surrounds the provision of genetic results for adult-onset
conditions to minors and their parents. We have designed a mixed-methods, longitudinal cohort study to collect
empirical evidence to advance this debate.
Methods: Pediatric participants in the Geisinger MyCode® Community Health Initiative with available exome
sequence data will have their variant files assessed for pathogenic/likely pathogenic variants in 60 genes designated
as actionable by MyCode. Eight of these genes are associated with adult-onset conditions (Hereditary Breast and
Ovarian Cancer Syndrome (HBOC), Lynch syndrome, MUTYH-associated polyposis, HFE-Associated Hereditary
Hemochromatosis), while the remaining genes have pediatric onset. Prior to clinical confirmation of results,
pediatric MyCode participants and their parents/legal guardians will be categorized into three study groups: 1)
those with an apparent pathogenic/likely pathogenic variant in a gene associated with adult-onset disease, 2) those
with an apparent pathogenic/likely pathogenic variant in a gene associated with pediatric-onset disease or with risk
reduction interventions that begin in childhood, and 3) those with no apparent genomic result who are sex- and
age-matched to Groups 1 and 2. Validated and published quantitative measures, semi-structured interviews, and a
review of electronic health record data conducted over a 12-month period following disclosure of results will allow
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for comparison of psychosocial and behavioral outcomes among parents of minors (ages 0–17) and adolescents
(ages 11–17) in each group.
Discussion: These data will provide guidance about the risks and benefits of informing minors and their family
members about clinically actionable, adult-onset genetic conditions and, in turn, help to ensure these patients
receive care that promotes physical and psychosocial health.
Trial registration: ClinicalTrials.gov Identifier: NCT03832985. Registered 6 February 2019
Keywords: Return of genomic results, Genomic medicine, Secondary findings, Pediatrics, BRCA1, BRCA2, Lynch
syndrome
Background
Exome and genome sequencing are increasingly inte-
grated into clinical care and research [1–7], providing an
opportunity to examine sequence data for pathogenic/
likely pathogenic variants in clinically actionable genes.
However, the potential benefits and harms of returning
genetic results to minors (ages 0–17) and their parents/
legal guardians (hereafter referred to as “parents”) are
matters of ongoing controversy — especially returning
genetic results for adult-onset conditions that are not
clinically actionable in childhood [8, 9]. The debate in-
tensified with the 2013 publication of recommendations
from the American College of Medical Genetics and
Genomics (ACMG) advising that clinicians notify their
patients, regardless of age, when a variant known or ex-
pected to increase disease risk was identified incidentally
through clinical sequencing in one of 56 clinically ac-
tionable genes not related to the test indication [10, 11].
Examples of clinically actionable conditions included
hereditary breast and ovarian cancer (HBOC) syndrome
(BRCA1/2), Lynch syndrome (MLH1, MSH2, MSH6 and
PMS2), and familial hypercholesterolemia (LDLR, APOB
and PCSK9), all of which have Centers for Disease Con-
trol and Prevention (CDC) tier-one level of evidence for
reducing morbidity and mortality in certain indications
[12]. Of the 59 genes currently considered by the ACMG
to be sufficiently actionable to merit patient analysis and
notification, 52 are associated with conditions that have
pediatric-onset or initiation of recommended risk reducing
procedures in childhood [10, 13]. The remaining seven
genes and their three associated conditions — HBOC
(BRCA1/2), Lynch syndrome (MLH1, MSH2, MSH6,
PMS2), and MUTYH-associated polyposis (MUTYH) — do
not typically lead to pediatric onset of disease [10, 13], and
thus, recommended surveillance and risk-reducing actions
are postponed until adulthood [14, 15].
Opposition to disclosure of adult-onset, clinically
actionable results to minors
ACMG’s recommendations and subsequent reaffirma-
tions regarding disclosure of secondary findings regard-
less of age [10, 11, 13] contrast with long-standing
recommendations and policy statements by professional
societies — including the ACMG [16] — to defer clinical
testing for adult-onset genetic conditions until minors
reach adulthood and can decide for themselves whether
to have testing. Professional guidelines recommending
against testing for adult-onset genetic conditions are
based on expert consensus and are focused on the trad-
itional normative standard — the best interests of the
minor — and cite concern about potential harms as well
as absence of clear medical benefit in childhood [16–23].
Potential harms and wrongs include psychological im-
pacts such as increased distress, negative impacts on
self-image, feelings of guilt or blame towards a family
member, and misattributing symptoms to the condition
[16, 24–26]. Additionally, disclosing an adult-onset gen-
etic result to a minor and their parent could disrupt
family relationships through differential treatment by par-
ents (including “vulnerable child syndrome”) or increased
parental anxiety and/or guilt [18, 24–26]. Of further con-
cern are the potential for discrimination by life or disabil-
ity insurers and stigmatization by peers [24, 25]. Finally,
some scholars have suggested that childhood testing fails
to respect the minor’s future autonomy by infringing upon
their “right to an open future” in which they can decide
for themselves whether or not to be tested [17, 18, 24–26].
These ethical arguments underpinning the professional
guidelines regarding genetic testing in childhood are
reviewed extensively elsewhere [18, 22, 24, 25].
Support for disclosure of adult-onset, clinically actionable
results to minors
In contrast, authors of the ACMG secondary finding
recommendations and other proponents of returning ac-
tionable clinical or research findings to all patients, re-
gardless of age, advocate for the broader interests of the
family and of the minor to be included in the risk-
benefit analysis [27]. For instance, they say, identifying
an adult-onset condition in a minor could prompt adult
relatives, including parents, to be tested for a potentially
life-threatening condition (hereafter referred to as “cas-
cade testing”), thereby protecting the interests of
dependent minors [10, 28]. Other proposed benefits of
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disclosing adult-onset genetic results to minors include
psychological benefits (e.g., the opportunity to adjust to
hereditary disease), the ability to inform life planning
(e.g., reproductive decision-making), and positive impact
on family relationships (e.g., promotion of realistic par-
ental expectations) [24, 26]. Additionally, some argue
that disclosing adult-onset, clinically actionable results
promotes autonomy, given that parents are best placed
to decide what is in their child’s best interest [24], ado-
lescents can contribute to informed decision-making
[24], and failing to disclose the variant could prevent
families from ever knowing their risk and, therefore,
could deny the minor the opportunity to know about
their risk in adulthood [27, 29]. Finally, there could be
legal incentives to disclose clinically actionable variants
to minors in states where courts recognize the “loss of
chance” doctrine [30, 31], a medical malpractice doctrine
that enables a plaintiff (patient) to bring suit against a
defendant (medical provider) whose breach of duty sub-
stantially reduced the chance of a more favorable out-
come (such as a delayed diagnosis diminishing the
chance of recovery from a pre-existing medical condi-
tion such as a variant conferring genetic risk). This
protocol paper focuses on the research components in-
volving human participants. The PROGRESS study team
also will be conducting legal research regarding the loss
of chance doctrine that will be discussed separately.
Parent and adolescent stakeholder views
While genetics providers, laboratories, and ethicists have
debated disclosure of clinically actionable results to mi-
nors and their parents, empirical studies have found
interest by parents and adolescents in receiving genetic
findings even if the minor’s health care is not immedi-
ately affected [32–39]. For example, half of a sample of
British adults felt that parents should be able to test
their children for adult-onset conditions, even while ac-
knowledging the validity of reasons for deferring testing
until adulthood (e.g., stigma, fear of discrimination) [38].
Nearly all participants in focus groups of parents of
pediatric participants in Geisinger’s MyCode® Commu-
nity Health Initiative wanted Lynch syndrome results for
their children, explaining that the importance of these
results to their children’s future health outweighed the
right of minors to make their own testing decisions once
they reach adulthood [35]. Adolescents in several studies
of stakeholders’ views of receiving results from genome-
scale sequencing also expressed interest in adult-onset
results and in being involved in decision-making about
whether to learn these results [33, 36, 37, 40]. Further-
more, student participants in the 2016 American Society
of Human Genetics (ASHG) DNA Day Essay Contest
were asked to name an adult-onset genetic condition
and defend or refute ASHG’s 2015 recommendation [17]
to defer testing for adult-onset conditions until adult-
hood. Of the 205 students who wrote about HBOC syn-
drome, 56% argued for BRCA1/2 testing before
adulthood, citing reasons such as prevention and life
planning [39].
As Mand et al. [24] note, “[m] ost arguments on both
sides are testable empirical claims, so far untested, ra-
ther than abstract ethical or philosophical positions.”
The limited evidence that does exist from minors who
underwent genetic testing has not substantiated the
negative psychosocial impacts anticipated by those op-
posed to the return of genetic information prior to
adulthood [41, 42]. Specific to a clinically actionable,
adult-onset condition, one study found that, female ad-
olescents (age 11–19 years) from BRCA1/2 families did
not differ in their general psychosocial adjustment as
compared to girls from breast cancer families without a
BRCA1/2 pathogenic/likely pathogenic variant and
peers without breast cancer in their family [43]. How-
ever, the available evidence concerning minors’ psycho-
social outcomes after receiving their own genetic
results is limited by a general focus on pediatric- rather
than adult-onset conditions, methodological differences
that hinder comparisons, and a lack of longitudinal
follow-up that would facilitate a clear understanding of
how adult-onset genetic findings affect minors and
their families over time [41, 42, 44]. There is less evi-
dence still about the optimal way of disclosing adult-
onset genetic risks to minors and their parents, should
evidence about the risks and benefits of disclosure sug-
gest such a policy.
Methods/design
The Pediatric Reporting of Genomic Results Study
(PROGRESS) seeks to determine how best to use genetic
information to guide care over the course of a minor’s
development in ways that maximize the physical and
psychosocial health of the minor and their family. Spe-
cifically, the study aims to use a mixed-methods, longi-
tudinal, observational cohort study to:
Aim 1: Determine whether anxiety, depression,
family functioning, and health-related quality of life
differ at 12 months post-disclosure among
adolescents (participants age 11-17), as well as
among parents of minors (participants age 0-17)
who: 1) receive an adult-onset result; 2) receive a
pediatric-onset result; or 3) do not receive a genetic
result.
Aim 2: Assess cascade testing uptake and initiation
of risk reduction behaviors among parents from
whom the minor inherited their adult- or
pediatric-onset genetic variant.
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Based on the limited available literature on the effects of
informing minors about their genetic condition or their
hereditary risk, we hypothesize that there will be no dif-
ferences in primary psychosocial outcomes in adoles-
cents and parents of minors who receive an adult-onset
finding, those who receive a pediatric-onset finding, and
those who do not receive a genetic finding.
Geisinger’s MyCode® community health initiative
PROGRESS will leverage experience from reporting clin-
ically actionable genetic findings to adults enrolled in
Geisinger’s MyCode® Community Health Initiative
(MyCode). As described elsewhere [45–47], Geisinger’s
MyCode project was launched in 2007 and serves as a
repository of blood, DNA, and serum samples from par-
ticipants who consent to broad, health-related research
use of their samples, including genomic analysis [48].
MyCode is a major resource for research that combines
information obtained from DNA and serum with health
information from the electronic health record and other
sources with the intention of improving the prevention,
diagnosis, and treatment of disease [47]. In 2012,
MyCode began enrolling minors with parental or legal
guardian consent and assent for enrollees age 7–17 years
[47]. In 2013, Geisinger began developing a process to
return clinically actionable results to adult MyCode par-
ticipants through the Genomic Screening and Counsel-
ing Program (GSCP) [46, 49]. This study will augment
the existing GSCP to return clinically actionable results
to minors and their parents, while collecting data to as-
sess psychological and behavioral outcomes among the
participants and their parents who receive a genetic
result.
Group definitions
Figure 1 summarizes the PROGRESS schema, which was
approved by the Geisinger Institutional Review Board
(IRB# 2018–0419). PROGRESS will use a mixed-
methods, longitudinal, observational cohort study design
to compare psychological outcomes and health-related
quality of life among three groups of pediatric MyCode
participants and their parent(s):
Group 1 - Those with a clinically confirmed, clinically
actionable, pathogenic/likely pathogenic variant in a
gene associated with one of four adult-onset diseases
for which no risk-reducing interventions are available
in childhood — HBOC, Lynch syndrome, MUTYH-as-
sociated polyposis, and HFE-Associated Hereditary
Hemochromatosis.
Group 2 - Those with a clinically confirmed, clinic-
ally actionable, pathogenic/likely pathogenic variant
in a gene associated with pediatric-onset disease or
with adult-onset disease for which risk reducing
interventions begin in childhood — all other ACMG
SF v2.0 genes (Additional File 1).
Group 3 - Those who do not have a potential
pathogenic/likely pathogenic variant identified, and
therefore do not receive a genetic result. Members
of this group, who will be frequency matched to
Group 1 and 2 participants based on age (+/- 2
years) and sex assigned at birth, will serve as
controls to assess outcomes among members of
Groups 1 and 2.
Recruitment/enrollment
Variant files from exome sequencing completed through
the DiscovEHR collaboration with Regeneron Genetics
Center [48] for any pediatric MyCode participants be-
tween the age of 0–17 years will be assessed for patho-
genic/likely pathogenic variants in 60 genes designated
as actionable by MyCode (Additional File 1) [50]. This
gene list includes the ACMG SF v2.0 list as well as bial-
lelic HFE C282Y variants [13] (Additional File 1). Before
clinical confirmation of variants in a CLIA-certified la-
boratory, a list of prospective pediatric participants will
be generated. Prospective participants will include mi-
nors with a potential pathogenic/likely pathogenic vari-
ant (Groups 1 and 2) and age- (+/− 2 years) and
biological sex-matched controls without such a variant
(Group 3).
The study team will mail the parents of these pro-
spective participants a letter describing the study, ele-
ments of informed consent, and an opportunity to opt
out of additional study contact. Two weeks later, re-
search staff will call those who have not opted out of
study contact and offer an in-person visit to discuss the
study. These staff, who will be blinded to potential par-
ticipants’ expected study group, will lead the in-person
consent process and obtain written documentation of
parental consent. Prospective participants and their par-
ents will be unaware of their potential group status dur-
ing recruitment and enrollment. Pediatric participants
ages 7–17 years will be engaged in the discussion and
have the opportunity to provide assent. If an additional
sample is required for MyCode study participation or
clinical confirmation of a potential pathogenic/likely
pathogenic variant [47, 49], this will be collected at the
time of the study consent/assent visit. At the time of en-
rollment, study staff will also ask parents for guidance
on how to disclose any results to their assenting children
(e.g., at the in-person disclosure consultation or at a sep-
arate consult). If a minor is unable to assent due to such
individual factors as a cognitive impairment, their par-
ent(s) will be asked to consent, and if consent is
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obtained, the parent(s) will be included in the study. Par-
ticipating minors who reach the age of majority (18
years) during the study will have the opportunity to par-
ticipate in an informed consent process at age 18. Partic-
ipants will be compensated for study participation after
each completed quantitative survey. A subset of parents
and adolescents will be invited to complete semi-
structured interviews and will be compensated further.
Exclusion criteria
Parents who decline participation and/or minors who do
not assent and their parents will be excluded from the
study. If assent/consent for PROGRESS are not given
and the minor is suspected to have an adult-onset result,
their sample will be held until the individual reaches 18
years of age and has re-consented to MyCode. If a minor
is suspected to have a pediatric-onset result but consent/
assent for PROGRESS are not given, their sample will
proceed to clinical confirmation and, if confirmed, will
follow established return procedures of the MyCode
GSCP without further quantitative or qualitative data
collection. Minors with an already identified genetic re-
sult for one of the 60 genes designated as actionable will
be excluded when generating the list of potential partici-
pants. Minors who have not undergone genetic testing
but have a known family history of a clinically actionable
variant in one of the 60 genes will be eligible to partici-
pate. Minors who have already undergone exome
Fig. 1 PROGRESS flow diagram. P=Parent of minor (ages 0–17), A = Adolescent (ages 11–17), ES = exome sequencing
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sequencing on a clinical basis will be excluded from
Group 1 or 2 if a variant in one of the 60 genes was
identified and will also be excluded from Group 3 in
light of their experience with genetic testing and poten-
tially complex medical history.
Sample size
Based on the current and anticipated pediatric participa-
tion in MyCode over the course of study enrollment, we
estimate that 8500 minors will be eligible for the study.
Given the expected rate of individuals with a patho-
genic/likely pathogenic variant in one of the target genes
— 2.3% of adult MyCode participants sequenced to date
[50] — we anticipate 195 pediatric participants will have
a genetic result. Ninety-eight (98) and 97 of these are
anticipated to be in Groups 1 (adult-onset result) and 2
(pediatric-onset result), respectively. Based on experi-
ence recruiting MyCode participants for additional stud-
ies, we estimate that 65% of the families approached will
consent to participate (internal data), leaving an esti-
mated 64 minors in Group 1 and 63 in Group 2. Assum-
ing conservatively that one parent enrolls for each child,
we anticipate there will be 64 parents in Group 1 and 63
parents in Group 2. Since roughly one-third of the mi-
nors receiving a result will be age 11–17 years, and
therefore eligible to contribute to data collection, we an-
ticipate an additional 42 adolescents in Groups 1 and 2
(21 in each group). The eligible pool of pediatric
MyCode participants with no genetic results to return
will be matched on an age (+/− < 2 years) and biological
sex distribution to Groups 1 and 2. We will approach
195 parents for inclusion in Group 3 and anticipate 65%
to consent for participation (n = 127). We also anticipate
an additional 42 adolescent participants in this group,
for a total sample size of 254 parents and 84 adolescent
participants across all three study groups.
For psychosocial outcomes in Aim 1, we have specified
a priori each pairwise comparison to be of interest.
Therefore, all calculations assume 80% power and 5%
significance level. Using the sample sizes noted above
with a 10% dropout, the minimum detectable effect size
(change in standard deviation units) for the key quanti-
tative psychosocial outcomes is 0.53, 0.45, and 0.46 for
the comparison of Group 1 vs. Group 2, Group 1 vs.
Group 3, and Group 2 vs. Group 3, respectively. If we
are successful in recruiting a second parent for some of
the minors, then we can expect the minimum detectable
difference to decrease. These effect sizes are considered
moderate in size and are less than the effect size seen in
a previous study that used the Hospital Anxiety and De-
pression scale in a sample of adolescent girls from fam-
ilies with BRCA1/2 variants [43].
The primary outcomes in Aim 2 are cascade testing
uptake and initiation of recommended risk reduction.
From the literature on cascade testing uptake in male
and female first-degree relatives of individuals with a
genetic condition [51–53], we estimate that approxi-
mately 50% of parents will complete cascade testing. To
account for the possibility that cascade testing in one
parent will spur uptake or negate the need for testing in
another, we will incorporate an intra-class correlation
value of 0.20. Based on the above sample size estimates,
the study will be able to detect a 21% difference in the
percentage of parents in Groups 1 compared to those in
Group 2 that complete cascade testing (e.g., 50% vs.
73%). Based on a previous study among unaffected
women with a pathogenic BRCA1/2 variant [54] and as-
suming that males pursue management behaviors at a
similar rate, we estimate that 65% of the parents will ini-
tiate risk reduction. Therefore, the study should be able
to detect an 18% difference in the percentage of parents
in Groups 1 compared to those in Group 2 who initiate
risk reduction (e.g., 65% vs. 85%).
Clinical confirmation and results disclosure
After consent/assent, DNA samples from participants
with a potential pathogenic/likely pathogenic variant will
be sent to a CLIA-certified clinical laboratory for con-
firmation [55]. Parents of minors with a clinically con-
firmed pathogenic/likely pathogenic result in one of the
actionable genes of interest will learn of their child’s re-
sult during an in-person consultation conducted by a
genetic counselor. Whether the minor learns of the re-
sult at the same disclosure consult as their parent(s) or
during a separate consult will be dictated by the selec-
tions that the parent and minor made at the time of en-
rollment. Parents of minors whose variants are not
confirmed clinically and participants without a patho-
genic/likely pathogenic variant (Group 3) will be sched-
uled for a study visit to notify them of their study group
assignment and remind them to follow-up with their
healthcare providers if they have significant personal or
family history of cancer or cardiovascular disease.
Data collection
Data will be gathered via quantitative surveys using vali-
dated measures, qualitative interviews with adolescents
and parents of minors, and review of electronic health
record and testing laboratory data to determine parents’
cascade testing uptake and initiation of risk reducing be-
haviors (Table 1).
Parent-participants will be asked to assess psychosocial
outcomes for themselves and for their children. Adoles-
cents will also participate in quantitative surveys and
qualitative interviews. Adolescents who are unable to
assent due to individual factors will be excluded from
quantitative and qualitative measures.
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Table 1 Outcomes, covariates, time points and validated measures in quantitative surveys
Data Collection Method Domain Validated Measure Time Points Completed
By
Aim 1 – Psychosocial Outcomes among Study Groups
Outcomes – All Groups
Quantitative survey General anxiety and depressiona Assessment of symptoms of DSM-IV anxiety
and depression in children [56]
Hospital Anxiety & Depression Scale [57]
T1, T2, T3, T4 P/A
Family functioning and cohesiona General Functioning subscale (short form) of
McMaster Family Assessment Device [58]
T1, T2, T3, T4 P/A
Health-related quality of lifea CDC HRQOL– 4 [59] T1, T2, T3, T4 P/A
Body image Body Image Scale [60] T1, T2, T3, T4 A
Self-esteem Rosenberg Self-Esteem Scale [61] T1, T2, T3, T4 A
Decision regret Decision Regret Scale [62] T2, T4 P
Patient satisfaction Genetic Counseling Satisfaction [63] T2 P
Covariates – All Groups
Psychological flexibility Acceptance and Action Questionnaire –
II [64]
Avoidance and Fusion Questionnaire for
Youth [65]
T1, T2, T3, T4 P/A
Lifestyle behaviors Physical activity, diet, smoking and
vaping [66]
Alcohol consumption [67]
T1, T3, T4 A
Information seeking Health Information Orientation Scale [68] T1 P
Personal utility Perceived utility of whole genome
sequencing [69]
T1, T2, T3, T4 P
Perceived risk Perceived cancer/heart disease risk [43, 70] T1, T2, T3, T4 P/A
Health literacy Brief health literacy scale [71] T1 P
Genomic literacy Knowledge of genome sequencing [72] T1 P
Outcomes – Participants with Genomic Result – Groups 1 and 2
Condition specific distress Children’s Revised Impact of Events Scale [73] T2, T3, T4 P/A
Adjustment to genetic information Psychological adaptation to genetic
information scale [74]
T2, T3, T4 P
Patient education and empowerment Health Education Impact Questionnaire [75] T2, T3, T4 P




Constructs for which validated
measures do not exist (e.g. vulnerable
child syndrome, right to an open future)
n/a
T2, T4 P/A




Aim 2 – Cascade Testing and Risk reduction Initiation among Group 1 and 2 Parents
Quantitative Survey Cascade testing uptakea Adapted from family communication of
genetic test results [76]
T4 P
Initiation of risk management behaviorsa Adapted from risk management in unaffected
women with pathogenic BRCA1/2 variants [54]
EHR review Cascade testing uptakea n/a T4 n/a
Initiation of risk management behaviorsa n/a
aPrimary outcomes, T1 = baseline; T2 = 1-month post-disclosure; T3 = 6-months post-disclosure; T4 = 12-months post-disclosure, P=Parent of minor (ages 0–17),
A = Adolescent (ages 11–17), EHR = Electronic Health Record
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Quantitative measures
Survey instruments that include published quantitative
measures (including those for anxiety/depression, psy-
chological flexibility, family functioning, quality of life,
body image, self-esteem, decisional regret, perceived
cancer/heart disease risk, genetic counseling satisfaction,
health literacy and genomic literacy) will be adminis-
tered at the time of enrollment (T1, Additional Files 2
and 3), one-month post disclosure/visit (T2, Additional
Files 4 and 5), six-months post disclosure/visit (T3),
and/or 12 months post disclosure/visit (T4) for all three
study groups [43, 54, 56–72, 76]. Additionally, Groups 1
and 2 will complete measures of condition-specific dis-
tress, adjustment to genetic information, family commu-
nication of genetic test results, and patient education
and empowerment one-month post disclosure (T2), six-
months post disclosure (T3), and/or 12-months post dis-
closure (T4) [73–75]. Longitudinal evaluation of a subset
of these measures will enable exploration of changes
over time. Table 1 summarizes the primary outcomes,
covariates, and published measures collected in each
study group. To ensure a satisfactory response rate, sur-
veys will be offered via multiple modalities, including by
phone, internet, and mail.
Additionally, parents of minors in Groups 1 and 2 will
be surveyed at 12 months post-disclosure (T4) to deter-
mine whether parents of minors with a genetic result
had cascade testing for the familial gene variant and
whether those found to carry the familial variant have
performed disease risk management behaviors (e.g.,
breast MRI for women with a pathogenic BRCA1 vari-
ant). The study team will also query electronic health re-
cords to capture cascade testing and risk management
behaviors among parents and will correspond with the
genetic testing laboratory that confirmed the minor’s
clinically actionable result to verify completion of cas-
cade testing in the family.
Qualitative measures
For Groups 1 and 2, the genetic counselor disclosing re-
sults will conduct a psychosocial assessment during the
disclosure visit. Genetic counselors are qualified to con-
duct psychosocial assessments and provide brief psycho-
social counseling [77]. The study clinical psychologists
will review the genetic counselor’s approach to psycho-
social assessments and provide input in accord with the
psychologists’ expertise. The disclosure will be audio re-
corded for future qualitative review by the study team.
Semi-structured interviews with a subset of up to 45
participants (or until thematic saturation is achieved)
will also be conducted by trained research staff using an
interpretive phenomenological approach to elucidate the
lived experience of adolescents and parents of minors re-
ceiving clinically actionable results [78]. Interviews will
be conducted using an established interview guide with
parents and adolescent participants from each group re-
ceiving results (Groups 1 and 2) at one-month (T2) and
12-months (T4) post disclosure (Additional Files 6 and
7). Approximately 15 interviews will be conducted
among parents of younger children (age 0–10 years), 15
additional interviews will be conducted with parents of
adolescents (age 11–17 years), and a final 15 interviews
will be conducted among adolescents. The semi-
structured format will enable data collection about pre-
selected constructs for which established measures do
not exist (such as “vulnerable child syndrome” and a
“right to an open future”) while allowing participants to
inform the study team of constructs that might not have
been considered. Interviews will be conducted through-
out the study’s duration to allow for assessment of
changes in experience that could be related to modifica-
tions in practice for the target conditions (e.g., changes
in risk management recommendations).
Data analysis
Aim 1: Analyses will focus on understanding if change
in the primary and secondary psychosocial outcomes
from pre- to post-disclosure differs significantly among
groups. The analysis of psychosocial change of the chil-
dren will employ linear mixed models (LMMs) with ran-
dom effects to capture correlation due to repeated
measures. We will use the parental reporting for this
analysis. The model will include random effects for the
intercept and slope, and an interaction between the
group indicator and time. If, after plotting the data, it is
found that the slope of each outcome variable is not lin-
ear, then the random slope parameter will be replaced
with a categorical, fixed-effects time variable. In either
model parameterization, contrasts can be set up to test
for change from baseline and compared among groups.
A priori it is of interest to compare each group to the
others; no post-hoc adjustment will be made. The
groups will be compared on baseline covariates. If any
are found to vary significantly, then the LMMs will be
extended to include the potentially confounding vari-
ables. If any of the primary psychosocial outcomes are
found to violate the normality assumption, we will con-
sider transforming those variables or using Generalized
Estimating Equations (GEEs). As a secondary analysis,
we will analyze the responses of adolescents aged 11–17
using the same approaches as above. Additional analyses
of the secondary outcomes will use regression models
appropriate for a given distribution; LMM for continu-
ous, logistic regression for binary/ordinal, and Poisson
regression for discrete counts, all with including random
effects to capture the within subject correlation due to
repeated measures.
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Aim 2: In this aim it is anticipated that any loss to
follow-up will have minimal impact on the outcomes, as
those data will be obtained from surveys at 12 months
post-disclosure and via the electronic health record
(EHR). Either self-report of cascade testing uptake or
presence of cascade test result in the EHR will count as
evidence of having had cascade testing.
Initiation of recommended disease risk reduction, a di-
chotomous variable, will be calculated for each parent
-participant who is found to carry the familial gene vari-
ant. As with the assessment of cascade testing uptake,
initiation of risk reduction will be determined by paren-
tal self-report at 12 months post-disclosure and via
query of the Geisinger EHR and of Keystone Health Infor-
mation Exchange. Participants will be considered to have
performed recommended risk reduction, if at 12 months
post-disclosure, they have had any of the risk reduction
procedures recommended for individuals with their gen-
etic condition. The analysis will use a random effects lo-
gistic regression model for cascade uptake. A random
effect for family will be included to account for the in-
herent correlation of the clustered analysis design that
collects data from parents. Comparisons between
Groups 1 and 2 for initiation of recommended risk re-
duction will use a binary logistic regression model. Both
models will include a covariate for Group membership.
As described above under Aim 1, the models will be ex-
tended to include baseline covariates that were found to
be different between groups.
Psychosocial support
Given concerns about the potential for adverse psycho-
social outcomes of returning adult-onset genetic results
to minors [16–18, 22–24, 26], genetic counselors return-
ing results, study staff administering instruments and
scoring quantitative measures, and those performing
qualitative interviews will notify the study’s pediatric
clinical psychologists of any clinically relevant scale
scores or psychological concerns that arise during data
collection and/or results disclosure. Moreover, a clinical
psychologist will check-in with all participants receiving
a genetic result one-month post-disclosure (T2, Groups
1 and 2), will conduct periodic psychosocial assessments
with adolescents with an adult-onset genetic result
(Group 1), and will schedule separate therapeutic inter-
actions with participants who exhibit clinically signifi-
cant distress or other psychological outcomes. The study
genetic counselor will also contact parents of children
and adolescents at one- and six-months post-disclosure
(T2, T3) to assess additional informational and support
needs. Any unanticipated adverse events will be reported
to the IRB and all adverse events (anticipated or un-
anticipated, serious or not, related or unrelated) will be
reported to the funding agency.
Additionally, an external, five-member Event Monitor-
ing Committee (EMC) [79, 80] has been convened to
provide additional, independent study oversight and pro-
tection of the psychosocial wellbeing of pediatric partici-
pants. The EMC has multidisciplinary expertise relevant
to the study (e.g., experts in adolescent health, bioethics,
and pediatric genetics) and will work with the study
team to address and prevent adverse events. In an effort
to prevent adverse events, the EMC has reviewed study
procedures and protocols and will have access to quanti-
tative and qualitative data during the study to identify
participant burden and psychosocial concerns. The EMC
also will have the capacity to respond immediately to
any serious adverse events, recommend changes to ad-
dress or mitigate the impact of those events, and identify
events that should lead to immediate cessation of the
study. The EMC will provide additional, independent
oversight to further safeguard pediatric participants’
welfare.
Study Status
As of March 16, 2020, 5212 pediatric participants have
consented to MyCode and provided a sample for gen-
omic analysis. Of those, 1878 have undergone exome se-
quencing as part of the DiscovEHR collaboration with
Regeneron Genetics Center [48]. Review of research se-
quence data has shown that seven are eligible to be sent
for clinical confirmation of an expected pathogenic/likely
pathogenic variant in one of the 60 genes designated as
actionable by MyCode. To date, seven parents of minors
have been approached for the study; none have con-
sented to participate.
Discussion
Integrating exome and genome sequencing into clinical
care and research has resulted in increasing opportun-
ities to examine sequence data for pathogenic/likely
pathogenic variants in clinically actionable genes. At
present, there is a discrepancy between ACMG’s recom-
mendation to return secondary findings without regard
to age and various guidelines recommending against
testing minors for adult-onset diseases due to concerns
about negative impacts. Data are needed to inform this
discussion and shape policies, protocols, and clinical care
[16, 44, 81].
This mixed-methods, longitudinal, observational co-
hort study is designed to address this evidentiary gap.
Psychosocial and behavioral data will allow for com-
parison of outcomes in adolescents and parents of
minors who receive an adult-onset result, in those
who receive a pediatric-onset result, and in those who
do not receive a genetic result. This is the first study
of which we are aware that will disclose adult-onset
results to minors and their parents and compare
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outcomes among study groups with and without an
adult-onset result in a real-world setting. This will pro-
vide several key opportunities to inform the debate regard-
ing the disclosure of these results to minors and their
parents through research and clinical testing (e.g., cascade
testing, return of variants as secondary findings). First, the
study will allow for examination of whether the psycho-
logical outcomes of adolescents and parents of minors re-
ceiving an adult-onset result through a supportive clinical
encounter differ from outcomes among those who receive
a pediatric-onset finding or those without a genetic finding.
The study has also been designed to collect quantitative
and qualitative data longitudinally, thereby allowing nu-
anced assessment of outcomes that have historically raised
concerns among clinicians and ethicists (e.g., parents may
treat their children as vulnerable, or actions taken in re-
sponse to the result may restrict children’s life choices).
The study also allows us to determine whether returning
adult-onset results to minors does, in fact, promote cas-
cade testing among parents and to describe behavioral out-
comes among parents. Finally, data collected to address the
study’s primary outcomes might also enable clinicians and
researchers to proactively identify which parents and ado-
lescents may benefit from additional supportive resources
when receiving clinically actionable, adult-onset genetic re-
sults, should evidence about the risks and benefits of dis-
closure suggest such a policy.
Several limitations are inherent in the study design
and population. The study population corresponds to
the local population which, although socioeconomi-
cally diverse and geographically rural, is of primarily
Northern European ancestry [47]. The age and sex
distribution of minors receiving a result will reflect
those in which a pathogenic/likely pathogenic variant
is identified, and therefore might not mirror MyCode
pediatric participants overall. Additionally, primary
analyses will be conducted using sex assigned at birth;
however, given that gender identity could affect psy-
chosocial outcomes, gender identity will also be col-
lected as part of the study. Although our study will
contribute critical data, additional studies will need to
replicate findings in other populations to resolve the
debate of whether to provide adult-onset genetic find-
ings to minors. Furthermore, the 12-month post dis-
closure follow-up for all participants might not
provide sufficient time for some of the psychosocial
outcomes to manifest. Similar studies with lengthier
time frames would provide information about psycho-
social impact as younger patients transition to deci-
sional maturity and as older minors transition to
adulthood.
In sum, the PROGRESS study will compare psycho-
social outcomes over time among minors who receive
an adult-onset genetic result and their parents, those
who receive a pediatric-onset result, and those who
do not receive a genetic result. It will also describe
cascade testing and risk-reduction behaviors among
parents of minors who receive a genetic result. The
study will provide much-needed data on the risks and
benefits of disclosing genetic results related to adult-
onset conditions to minors and their parents, inform-
ing policy and practice in this contested area of gen-
omic medicine.
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